PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic Mar 26, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner
Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.
Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Hussein Tawbi, MD, PhD - Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options Mar 26, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 10, 2025.

Taking the Front Seat in Metastatic Melanoma Care: Guidance on Using PD-1/LAG-3 Platforms as Modern First-Line Options

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Hussein Tawbi, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Boxer Capital, LLC; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche AG; Iovance Biotherapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Medicenna; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Dragonfly Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation and RAPT Therapeutics. Research Support to Institution.

Faculty/Planner
Georgina Long, AO, BSc (Hons 1, UM), PhD, MBBS, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agenus Inc.; Amgen Inc; Array Biopharma; AstraZeneca; Bayer AG; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Evaxion Biotech; Hexal AG (Sandoz Company); Highlight Therapeutics S.L.; IO Biotech; Immunocore; Innovent Biologics USA; Merck Sharpe & Dohme; Novartis; PHMR Ltd; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Scancell; and SkylineDX B.V.

Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon Mutations: How to Navigate the Expanding Options and Increasing Complexity Mar 14, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SKH865. CME/MOC/AAPA/IPCE credit will be available until March 20, 2025.

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

Support
This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Faculty/Planner
Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.
Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.

Faculty/Planner
Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.
Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in Lilly.

Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer Mar 14, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty/Planner
Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.

Faculty/Planner
Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.

Faculty/Planner
Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.

Prof. Laurence Albiges, MD, PhD - Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors and Preparing for Innovative Delivery Approaches in the Clinic Mar 14, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GUE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 7, 2025.

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Matthew D. Galsky, MD - Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum Mar 14, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JSQ865. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.

Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through independent educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck & Co., Inc.; and Seagen and Astellas.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Matthew D. Galsky, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bicycle Therapeutics; Bristol Myers Squibb; Curis, Inc.; Daiichi Sankyo, Inc.; EMD Serono Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb and Merck & Co., Inc.

Faculty/Planner
Shilpa Gupta, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; EMD Serono Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Pfizer; and Seattle Genetics (Seagen Inc.).
Grant/Research Support from Bristol Myers Squibb; EMD Serono Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; QED Therapeutics, Inc.; and Seattle Genetics (Seagen Inc.).
Speaker for Bristol Myers Squibb; Gilead Sciences, Inc.; and Seattle Genetics (Seagen Inc.).

Faculty/Planner
Andrea Necchi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; CatalYm; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer; and Seagen Inc.
Grant/Research Support from Bristol Myers Squibb; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc.

Adam Friedman, MD, FAAD - Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid Mar 14, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.

Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Adam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.
Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.
Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.

Co-Chair/Planner
Shawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.

Co-Chair/Planner
Peter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.
Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.
Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.

Co-Chair/Planner
Professor Dedee Murrell has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.

Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations Mar 14, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Klaus F. Rabe, MD, PhD, FERS - Episode 2: Which Patients Should Receive Targeted Biologic Therapy and When? Mar 12, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/AGP865. CME/MOC/AAPA credit will be available until March 7, 2025.

Overcoming Challenges in the Treatment of Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma: Comparing Approaches to the Use of Targeted Biologic Therapy With Experts Around the World

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Leonard B. Bacharier, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Aravax; AstraZeneca; Avillion LLP; DBV Technologies; GlaxoSmithKline; Kinaset Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; and Vertex Pharmaceuticals Incorporated.
Speaker for Regeneron Pharmaceuticals Inc. and Sanofi.
Other Financial or Material Support for Patents and Royalties from Elsevier.

Faculty/Planner
Klaus F. Rabe, MD, PhD, FERS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; CSL Behring; Regeneron Pharmaceuticals Inc.; and Sanofi.
Speakers Bureau participant with AstraZeneca; BERLIN-CHEMIE AG; Boehringer Ingelheim International GmbH; CHIESI USA, Inc.; The Menarini Group; Regeneron Pharmaceuticals Inc.; and Sanofi.

Presenter
Arzu Yorgancioglu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abdi İbrahim; AstraZeneca; CHIESI USA, Inc.; and GlaxoSmithKline.
Grant/Research Support from Sanofi.
Speaker for Abdi İbrahim; AstraZeneca; Bilim Pharmaceuticals; CHIESI USA, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.

Leonard B. Bacharier, MD - Episode 4: What Are Our Most Significant Challenges in Treating Patients With Moderate to Severe Asthma and What Can We Learn From Each Other? Mar 12, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected